Boston Scientific Reports Strong Second-Quarter Results but Lowers Full-Year Outlook
Boston Scientific reported second-quarter revenues of $5.4 billion, reflecting a 7.5% year-over-year increase driven largely by its cardiovascular segment and the adoption of its FARAPULSE pulsed field ablation system. Despite strong performance in key areas like medsurg and endoscopy, the company revised its full-year outlook downward for both revenue growth and earnings per share (EPS). Previously anticipating 2026 revenue growth between 7% to 8.5%, Boston Scientific now expects sales growth of approximately 5.5% to 6.5%. The EPS guidance was also reduced from $3.34–$3.41 to $3.28–$3.32. The revised outlook is attributed in part to a planned global restructuring program aimed at achieving cost efficiencies and supporting long-term growth, which the company expects will result in significant upfront costs but annual savings of around $500 million over time. The announcement led to an immediate drop in Boston Scientific’s stock price by more than 5% on July 29.
Tickers: $BSX